证券简称：通策医疗 证券代码：600763 编号：临 2023-045 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 杭州宝群实业集团有限公司（以下简称"宝群实业"）持有通策医疗股份有限 公司（以下简称"公司"）股份总数 108,232,000 股，占总股本的 33.75%；本次质押 股份数为 6,800,000 股，占宝群实业所持有本公司股份数 6.28%，占本公司总股份数 的 2.12%；同时办理解除质押股份数为 6,750,000 股，占宝群实业所持有本公司股份 数的 6.24%，占本公司总股份数的 2.11%。宝群实业质押股份总数为 53,980,000 股， 占宝群实业所持有本公司股份数的 49.87%，占本公司总股份数的 16.84%；宝群实业 的一致行动人吕建明先生持股总数 1,303,500 股，占总股本的 0.41%，并无质押；宝 群实业已质押股份数占宝群实业及其一致行动人所持有本公司股份数的 49.28%，占本 公司总股份数的 16.84%。 一、上市公司股份质押情况 2023 年 ...

证券代码：600763 证券简称：通策医疗 编号：临 2023-044 通策医疗股份有限公司 关于 2023 年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 通策医疗股份有限公司（以下简称"公司"）2023年半年度业绩说明会(以 下简称"说明会")于2023年9月4日（星期一）15：00-16：30于上海证券交易 所上证路演中心以网络互动方式召开。公司董事长吕建明先生、总经理王毅女 士、财务总监徐国喜先生、董事会秘书张华先生等出席本次说明会，与投资者 进行了充分的沟通和交流，投资者交流的主要问题及回复概要如下： 1.2023年半年度业绩情况说明。 2023年H1，公司口腔医疗门诊量达158万人次，实现总营业收入13.63亿 元，比去年同期增长3.38%，公司实现归属于上市公司股东的净利润3.04亿元， 同比增长2.99%。 2、公司2023年上半年种植牙颗数？ 2023H1 种植牙颗数 23500、同比+33.8%，集采落地后种植牙增速有明显提升。 3、2023H1种植牙集采客单价和非集 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： http://roadshow.sseinfo.com/）； 会议召开方式：上证路演中心视频直播和网络互动； 投资者可于 2023 年 09 月 01 日(星期五)16:00 前登录上证路演中心网站 首页点击"提问预征集"栏目或通过公司邮箱 lianghao@eetop.com 进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 证券简称：通策医疗 证券代码：600763 编号：临 2023-043 通策医疗股份有限公司 关于召开2023年半年度业绩说明会的公告 通策医疗股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年上半年经 营成果、财务状况，公司计划于 2023 年 9 月 4 日下午 15:00-16:30 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 1,362,665,563.42, representing a 3.38% increase compared to CNY 1,318,172,450.10 in the same period last year[13]. - The net profit attributable to shareholders of the listed company was CNY 304,412,526.52, up 2.99% from CNY 295,587,915.31 in the previous year[13]. - The net cash flow from operating activities increased by 12.96% to CNY 294,150,733.29, compared to CNY 260,411,191.10 in the same period last year[13]. - The total assets at the end of the reporting period were CNY 5,571,763,181.30, an 8.10% increase from CNY 5,154,452,885.95 at the end of the previous year[13]. - The net assets attributable to shareholders of the listed company increased by 9.07% to CNY 3,611,051,602.19 from CNY 3,310,746,839.97 at the end of the previous year[13]. - Basic earnings per share for the first half of 2023 were CNY 0.95, a 3.26% increase from CNY 0.92 in the same period last year[14]. - The company reported a net profit excluding non-recurring gains and losses of CNY 292,945,014.43, which is a 2.32% increase from CNY 286,293,050.61 in the previous year[13]. - The company reported a revenue of 20,714,551.59 from product sales to Zhejiang Tongce Ophthalmology Hospital Investment Management Co., an increase from 17,531,027.10 in the previous period, representing a growth of approximately 12.43%[65]. - The company recognized service fees of 1,759,623.55 from Hangzhou Cunjing Women and Children Hospital, indicating a new revenue stream[65]. Operational Highlights - The company served 1.58 million outpatient visits in H1 2023, reflecting strong demand for its dental services[18]. - The company operates 74 medical institutions and employs 2,056 doctors, with a total operating area exceeding 240,000 square meters[18]. - The company is focused on the "Dandelion Plan" to accelerate the establishment of branch hospitals, achieving breakeven faster than competitors[18]. - The company has implemented a doctor shareholding plan to enhance growth prospects post-pandemic[18]. - The company has established five regional dental hospital groups in Zhejiang Province to optimize resource allocation and expand market share[19]. - The company employs a "Regional General Hospital + Branch" model to enhance brand influence and operational efficiency[20]. - The team diagnosis model aims to improve patient satisfaction by providing tailored medical services through multidisciplinary teams[21]. - The company has been recognized as one of the "China Excellent Management Companies" by Deloitte for four consecutive years from 2018 to 2022[18]. - The company is implementing a supply chain optimization project in collaboration with Deloitte, focusing on disease management and maximizing patient value, aiming to establish a standardized and intelligent supply chain management system[22]. - The company has adopted a "customer lifetime management model" to enhance service quality and marketing effectiveness, emphasizing transparency and effective diagnosis as key marketing strategies[23]. - The company offers a range of dental services at different price points to cater to diverse customer needs, with all dental hospitals obtaining medical insurance qualifications within approximately 6 months of opening[24]. Market Insights - The dental healthcare market in China is expected to continue expanding, with a high prevalence of dental diseases and low treatment rates, driven by an aging population and increasing health awareness[25]. - The dental service market in China was valued at approximately 110 billion yuan in 2022, with a projected annual growth rate of 11.4% for patient visits and 9.0% for average treatment costs over the past five years[26]. - The company supports the national dental implant centralized procurement policy, which is expected to lead to a surge in demand for dental implants in the second half of 2023 following the policy's full implementation in April 2023[28]. Financial Position - The company's gross profit margin and net profit margin levels remained stable, with a focus on cost control and efficiency improvements[37]. - The main business revenue composition showed that implant services generated CNY 22.87 million (17.9% of total revenue), orthodontics CNY 22.30 million (17.4%), pediatric dentistry CNY 24.26 million (19.0%), and restorative services CNY 21.63 million (16.9%), with overall growth in the restorative segment at 7.8%[38]. - The total outpatient visits reached 158.5 million in H1 2023, an increase of 11.4% compared to 142.3 million in H1 2022, with significant growth in Zhejiang province[40]. - The company’s revenue from dental services in Zhejiang province accounted for 92% of total revenue, with a 3.2% increase year-on-year, while revenue from outside Zhejiang decreased by 2.1%[39]. - The company implemented a "general hospital + branch hospital" model, which has helped reduce marketing costs and maintain service quality across its branches[30]. - The company’s cash flow from operating activities increased by 12.96% to CNY 294.15 million, while cash flow from investing activities showed a significant decline of 102.84%[42]. - The company aims to enhance its operational capabilities through target management and further cost reduction initiatives[37]. Investment and Expansion - The company invested ¥501,199,963.00 in HeRen Technology, acquiring a 19% stake[47]. - The company has completed the construction of its headquarters and expects it to be operational by 2024, which will support future growth initiatives[69]. - The company has signed a management agreement with its subsidiary, which will manage dental hospitals in Wuhan, Chongqing, and Xi'an, with a management fee estimated not to exceed RMB 30 million[74]. - The company has established partnerships with various property management firms to secure prime locations for its operations[78][79][80][81][82]. - The company is actively pursuing growth through both management agreements and strategic leasing of properties to support its dental services[75][76][77]. Governance and Compliance - The company has established a multi-tier governance structure, including a board of directors and various specialized committees[117]. - The company has completed rectifications following disciplinary actions from the Shanghai Stock Exchange, enhancing compliance and information disclosure quality[60]. - The company has committed to maintaining independent operations and protecting the interests of minority shareholders[58]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties during the reporting period[59]. - The company has established a comprehensive environmental management network, adhering to national environmental protection laws and regulations, and has implemented 15 systems for the management of medical waste[55]. Environmental Responsibility - The company has not been listed as a key pollutant discharge unit by the national environmental protection department, indicating a commitment to environmental responsibility[55]. - The company has implemented strict wastewater treatment protocols, ensuring all pollutants are pre-treated and meet standards before discharge[55]. - The company actively promotes energy-saving measures across its hospitals, contributing to the concept of green hospitals and reducing carbon emissions[56]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 87,536[86]. - The largest shareholder, Hangzhou Baoqun Industrial Group Co., Ltd., holds 33.75% of the shares, totaling 108,232,000 shares[87]. - The second-largest shareholder, China Industrial Bank Co., Ltd. - Central European Medical Health Mixed Securities Investment Fund, holds 4.89% with 15,683,613 shares[87]. - The company has no changes in share capital structure during the reporting period[86]. - The top ten shareholders hold a significant portion of the company's shares, with the largest holding being 33.75%[87]. Risk Factors - The company is facing competition risks in the dental market, which is a trillion-level market in China, with a significant portion of dental needs still unmet[50]. - The company plans to enhance its presence in the low-end market while maintaining its advantages in the mid-to-high-end market to ensure stable profitability[50]. - The company has implemented a comprehensive medical quality management system to mitigate medical risks and improve service quality across its hospitals[50].

2、程序合法。公司第九届董事会第二十次会议聘任财务总监的程序、表决结 果符合《公司法》、《公司章程》的有关规定。 通策医疗股份有限公司 独立董事关于第九届董事会第二十次会议的独立意见 作为通策医疗股份有限公司（以下简称"公司"）的独立董事，根据《关于 在上市公司建立独立董事制度的指导意见》、《公司章程》、《公司独立董事制度》 等有关规定，认真审阅了相关材料，基于独立判断立场，就公司第九届董事会第 二十次会议聘任财务总监之事项发表如下独立意见： 1、相关人员的任职资格合法，根据公司提供的相关人员的个人履历等相关材 料，认为：公司第九届董事会第二十次会议聘任的财务总监具有多年的企业管理 和相关工作经历，接受的专业教育及学识符合公司治理和经营发展的需要，可以 胜任所聘任工作。 未发现上述人员有《公司法》第 146 条规定的禁止担任公司高级管理人员职 务的情形以及被中国证监会处以证券市场禁入处罚且禁入期限未满的情形或被 上海证券交易所惩戒的情形。上述人员具备中国有关法律、法规以及《公司章程》 规定的任职资格。 张轶男 2023 年 8 月 24 日 综上所述，同意公司董事会聘任徐国喜先生为公司财务总监。 独立董事签字 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 通策医疗股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日召开第九届董 事会第二十次会议，审议通过《关于聘任公司财务总监的议案》。经公司总经理提名， 并通过董事会提名委员会审核，同意聘任徐国喜先生为公司财务总监，任职期限从公 司董事会审议通过之日起至第九届董事会届满之日止。通策医疗总经理王毅女士将不 再兼任公司财务总监。 徐国喜先生具备与岗位相应的专业能力和从业经验，不存在《公司法》规定的不 能担任公司高级管理人员的情形，未受过中国证监会、证券交易所及其他有关部门的 处罚或惩戒，也不存在其他不得担任上市公司高级管理人员之情形。截止本公告披露 日，徐国喜先生未持有公司股份，与公司控股股东、实际控制人以及其他董事、监事、 高级管理人员和持股 5%以上的公司股东之间不存在关联关系。 公司独立董事就聘任徐国喜先生担任公司财务总监的议案发表了同意的独立意 见，具体内容详见公司于同日披露的《通策医疗股份有限公司独立董事关于第九届董 事会第二十次会议的独立意见》。 证券简 ...

证券简称：通策医疗 证券代码：600763 编号：临 2023-041 通策医疗股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 通策医疗股份有限公司（以下简称"公司"）第九届董事会第二十次会议通知以 电子邮件、电话等方式发出，会议于 2023 年 8 月 24 日在浙江省杭州市西湖区灵溪北 路 21 号合生国贸中心 5 号楼会议室以现场结合通讯表决方式召开。 本次会议由公司董事长吕建明先生主持。会议应出席董事 7 人，实际出席 7 人， 公司监事以及公司高管列席本次会议，会议的通知、召开符合《公司法》、《公司章 程》及有关法律法规规定，会议决议合法有效。 二、董事会会议审议情况 会议审议并通过以下议案： 1、审议通过《通策医疗股份有限公司 2023 年半年度报告》和《通策医疗股份有 限公司 2023 年半年度报告摘要》 公司按照有关法律法规和上海证券交易所股票上市规则的要求编制 2023 年半年 度报告。具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《 ...

证券简称：通策医疗 证券代码：600763 编号：临 2023-025 通策医疗股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩 暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 05 月 08 日(星期一)下午 15:00-16:30 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 04 月 26 日(星期三)至 05 月 05 日(星期五)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lianghao@eetop.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 通策医疗股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务 状况，公司计划于 2 ...

Business Expansion and Strategy - In 2022, Tongce Medical added 36 new dental medical institutions, with 17 established in that year alone, achieving breakeven faster than peers[3]. - The company aims to focus on the dental market in Zhejiang Province, targeting a "Double Hundred Plan" to establish 100 hospitals with 10 billion RMB in revenue[4]. - Tongce Medical's investment in HeRen Technology is part of a strategy to build a standardized hospital management system and enhance operational efficiency[4]. - The company has redefined its women's and children's health strategy to focus on non-profit models, leveraging its assets to participate in the Yihao Fund for risk mitigation[5]. - The dental implant procurement policy is expected to create a significant market demand surge in 2023, following a two-year educational campaign[5]. - Tongce Medical's long-term vision includes becoming a leading dental healthcare platform, with a focus on sustainable profitability and growth[3]. - The company emphasizes the importance of adapting to the national dental implant procurement policy to enhance service quality and affordability[5]. - The company aims to enhance accessibility to dental services, reflecting a mission to improve the quality of life for ordinary families[6]. - The company plans to leverage its extensive medical team to maintain rapid growth in the future, with over 1,000 medical staff reserved for new facilities[31]. - The company focuses on a "General Hospital + Branch Hospital" model to optimize resource allocation and reduce marketing costs[54]. - The company is expanding its presence in key regions such as the Yangtze River Delta and the Pearl River Delta, establishing large-scale dental hospital groups[82]. Financial Performance - In 2022, the company's operating revenue was approximately ¥2.72 billion, a decrease of 2.23% compared to 2021[21]. - The net profit attributable to shareholders was approximately ¥548 million, down 21.99% from the previous year[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥525 million, reflecting a decrease of 21.73% year-on-year[21]. - The net cash flow from operating activities was approximately ¥670 million, a decline of 28.67% compared to 2021[21]. - The company's total assets increased by 4.03% year-on-year, reaching approximately ¥5.15 billion by the end of 2022[21]. - The basic earnings per share decreased to ¥1.71, down 21.92% from ¥2.19 in 2021[23]. - The company reported a total of ¥23 million in non-recurring gains and losses for 2022, with significant contributions from government subsidies and other income[25]. - The weighted average return on equity decreased to 17.57%, down 10.36 percentage points from the previous year[23]. - The company reported a total comprehensive income of CNY 597,629,978.66, down from CNY 816,601,546.51 in the previous year[194]. - The company reported a decrease in accounts payable from ¥173,533,005.21 in 2021 to ¥140,519,901.44 in 2022, a decline of about 19.03%[190]. Market Potential and Trends - The dental healthcare market in China is still in its infancy, with a vast potential for growth, particularly in Zhejiang Province[4]. - The dental service market in China reached approximately 110 billion yuan in 2022, with a projected compound annual growth rate (CAGR) of over 15% from 2023 to 2026[44]. - The prevalence of malocclusion in China is approximately 74%, indicating a potential patient base of around 1.04 billion people, with the orthodontic market expected to reach 66 billion yuan by 2025, growing at a CAGR of 14%[45]. - The penetration rate of dental implants among elderly individuals aged 65-74 is expected to increase, with a projected potential of 12.1 million implants by 2025[46]. - Over 50% of the population aged 12-74 shows signs of gum disease, highlighting a significant market for periodontal treatments[47]. - The dental caries rate among children under 5 years old is as high as 71.9%, indicating a growing demand in the pediatric dental market[47]. Operational Efficiency and Innovations - The company emphasizes its commitment to solving the issue of scalable services through organizational, technological, and business model innovations[6]. - The company has established a "Doctor Group + Hospital Platform" dual-driven core capability to enhance service quality and operational efficiency[54]. - The Ningbo Dental Hospital has developed into a group with 12 specialized dental institutions, emphasizing talent recruitment and innovation[50]. - The establishment of the Ningbo Doctor Innovation Station aims to enhance research and clinical capabilities, providing new opportunities for hospital development[50]. - The company is focused on integrating technology, engineering, art, and medical science in its operations[6]. - The company continues to implement the Amiba management philosophy, enhancing team diagnosis models to accurately reflect operational data, including monthly analysis of revenue and patient visits[87]. Governance and Compliance - The company has established a dedicated team for investor relations, facilitating communication through various channels including analyst and investor meetings[96]. - The company actively fulfills its information disclosure obligations, enhancing the quality and accuracy of its disclosures[96]. - The company has implemented measures to strengthen its internal control and risk management systems[96]. - The company has continuously improved its governance structure and decision-making mechanisms to ensure its independence as a listed entity[98]. - The company has not faced any situations of competing with its controlling shareholders or their other enterprises[98]. - The company has established a commitment to prioritize its interests in case of potential competition with related parties, ensuring operational independence[136]. Environmental Responsibility - The company has committed to carbon reduction measures, although specific metrics on CO2 equivalent emissions reduction were not provided[132]. - The company actively engages in energy-saving practices across its hospitals, contributing to the concept of a green hospital[133]. - The company has established a comprehensive environmental management network, adhering to various environmental protection laws and regulations, including the Environmental Protection Law and the Water Pollution Prevention Law[131]. - The company has implemented strict waste management protocols, including 15 systems for the classification and treatment of medical waste, effectively reducing environmental harm[131]. Future Outlook - The company aims for a performance growth of no less than 25% in 2023, focusing on high-quality development and strategic planning[83]. - The company plans to implement a "three-three" management model to enhance operational efficiency and resource allocation across its facilities[84]. - The company plans to launch the "Three Leaves Children's Oral Health Project" in 2023, which will include a dedicated operations department and a membership system to improve service quality[93]. - The company plans to invest approximately 4 billion yuan in acquiring a 19% stake in a technology company in 2023[123]. - The construction of the Hangzhou Oral Hospital headquarters and other projects is expected to require around 1 billion yuan in 2023[124].

Financial Performance - The company's Q1 2023 revenue reached ¥674,535,941.41, representing a year-on-year increase of 3.04%[4] - Net profit attributable to shareholders was ¥168,971,152.17, with a year-on-year increase of 1.49%[4] - Total operating revenue for Q1 2023 was 674,535,941.41 RMB, an increase of 3.1% compared to 654,632,302.73 RMB in Q1 2022[16] - Net profit for Q1 2023 reached 197,535,406.14 RMB, compared to 190,330,516.78 RMB in Q1 2022, marking an increase of 3.8%[17] - Earnings per share for Q1 2023 was 0.53 RMB, slightly up from 0.52 RMB in Q1 2022[17] Cash Flow - The net cash flow from operating activities was ¥156,768,252.79, showing a significant increase of 141.92% compared to the previous year[4] - Cash flow from operating activities in Q1 2023 was 615,794,420.54 RMB, compared to 583,150,305.67 RMB in Q1 2022, indicating a growth of 5.6%[17] - The net cash flow from operating activities for Q1 2023 was $156,768,252.79, an increase from $64,802,118.31 in Q1 2022, representing a growth of approximately 142.5%[18] - The cash inflow from operating activities totaled $627,885,029.71, compared to $589,571,939.02 in the same period last year, marking an increase of approximately 6.4%[18] - The company experienced a net increase in cash and cash equivalents of $332,063,079.51 in Q1 2023, contrasting with a decrease of -$109,303,293.92 in Q1 2022[19] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥5,568,084,323.16, an increase of 8.02% from the end of the previous year[5] - Current assets totaled approximately ¥1.44 billion, up from ¥1.11 billion year-over-year, indicating a growth of around 29.3%[13] - The total liabilities as of Q1 2023 amounted to 1,752,319,733.77 RMB, up from 1,536,223,702.61 RMB in the previous year, reflecting a growth of 14.1%[15] - Long-term borrowings increased significantly to 280,000,000.00 RMB from 28,800,000.00 RMB in the previous year, indicating a rise of 871.0%[15] - The total equity attributable to shareholders of the parent company was 3,479,717,992.05 RMB, compared to 3,310,746,839.97 RMB in the previous year, an increase of 5.1%[15] Operational Highlights - The number of new clinics opened under the "Dandelion" brand reached 37, contributing ¥125,780,000 in revenue, a year-on-year growth of 60%[5] - The company expects to deliver 8 new hospitals for operation in 2023[5] - The company reported a significant increase in long-term equity investments, totaling approximately ¥245.58 million, up from ¥243.07 million[14] - The company has a strong shareholder base, with the top shareholder holding approximately 33.75% of the total shares[11] Cost and Expenses - Total operating costs for Q1 2023 were 459,481,476.70 RMB, up from 436,620,005.50 RMB in Q1 2022, reflecting a rise of 5.1%[16] - Research and development expenses for Q1 2023 totaled 11,077,832.40 RMB, an increase from 10,554,549.35 RMB in Q1 2022[16] Other Financial Metrics - The weighted average return on equity decreased by 0.64 percentage points to 4.98%[4] - The company reported a significant increase in long-term borrowings by 872.22% due to new bank loans[8] - The company has not reported any significant changes in its financing or margin trading activities as of the report date[11] - There are no significant reminders or alerts regarding the company's operational status during the reporting period[12]